Evaluation of the effectiveness of doxycycline in the treatment of outpatients with Covid-19

Phase 2

• Conditions: COVID-19, virus identified.; COVID-19; U07.1

• Registration Number: IRCT20160523028008N16
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

Minimum age 18 and maximum age 80 years
Do not take doxycycline for the last five days
Patients with definitive diagnosis of Covid 19 (RT-PCR) candidate for outpatient treatment with pulmonary involvement score on CT scan equal to or below 8
Patients suspected of Covid-19 based on clinical signs and manifestations of CT scan and laboratory results candidate for outpatient treatment.

Exclusion Criteria

Hospitalization
Patients with no indications for outpatient treatment based on national protocol.
pregnancy
Patients with a history of allergic reaction or Doxycycline.
Underlying disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement of clinical symptoms. Timepoint: Start of study and 3, 7, 14 days after study. Method of measurement: Questionnaire - telephone follow-up and.;Hospitalizations. Timepoint: 7 and 14 days after study. Method of measurement: Telephone follow up.;Mortality rate. Timepoint: 7 and 14 days after study. Method of measurement: Telephone follow up.

Secondary Outcome Measures

Name	Time	Method
Side effects of doxycycline. Timepoint: 7 and 14 days after study. Method of measurement: Telephone follow up.